Trial Profile
Phase IIa Study to Characterize the Effects of the Spiegelmer NOX H94 on Anemia of Chronic Disease in Patients With Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs Lexaptepid pegol (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors NOXXON Pharma AG
- 24 Apr 2014 New trial record